

Amendments to the Claims

1. (Currently amended) A peptide composed of an amino acid sequence selected from the group consisting of:

CRAHSFGSPRPLPVV (SEQ ID NO:1),
SRAHSFGSPRPLPVV (SEQ ID NO:2), and
CRAHSFVSPRPLPVV (SEQ ID NO:3), ~~and~~
~~QPDPHLMMWKLPQFP (SEQ ID NO:4).~~

2-3 (Cancelled)

4. (Currently amended) A peptide which is composed of a fragment of an amino acid sequence ~~a peptide~~ selected from the group consisting of:

CRAHSFGSPRPLPVV (SEQ ID NO:1),
SRAHSFGSPRPLPVV (SEQ ID NO:2), and
CRAHSFVSPRPLPVV (SEQ ID NO:3), ~~and~~
~~QPDPHLMMWKLPQFP (SEQ ID NO:4);~~

said peptide being between 8 to 14 amino acids in length, wherein said peptide fragment is capable of modulating a fibrin fragment E activity.

5-9 (Cancelled)

10. (Previously amended) A peptide according to claim 1, wherein said activity is stimulation of cell proliferation or

angiogenesis.

11. (Previously amended) A fusion peptide which comprises a first portion having the amino acid sequence of a peptide according to claim 1 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

12-19 (Withdrawn)

20. (Cancelled)

21. (Previously amended) A composition comprising a peptide according to claim 1 in association with a pharmaceutically acceptable carrier or diluent.

22-24 (Withdrawn)

25-26 (Cancelled)

27-29 (Withdrawn)

30 (Cancelled)

31. (Previously added) A fragment of a peptide according to claim

4 wherein said activity is stimulation of cell proliferation or angiogenesis.

32. (Previously added) A fusion peptide which comprises a first portion having the amino acid sequence of a fragment of a peptide according to claim 4 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

33-35 (Withdrawn)

36. (Previously added) A composition comprising a fragment of a peptide according to claim 4 in association with a pharmaceutically acceptable carrier or diluent.

37. (Withdrawn)

38. (Re-presented-formerly claims 2 and 3) A peptide which is composed of a variant of an amino acid sequence selected from the group consisting of:

CRAHSFGSPRPLPVV (SEQ ID NO:1),

SRAHSFGSPRPLPVV (SEQ ID NO:2), and

CRAHSFVSPRPLPVV (SEQ ID NO:3),

said peptide having one or two conservative amino acid substitutions with respect to said amino acid sequence, wherein

the peptide is capable of modulating a fibrin fragment E activity.